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Scope: Broccoli accumulates 4-methylsulphinylbutyl glucosinolate
(glucoraphanin) which is hydrolyzed to the isothiocyanate sulforaphane.
Through the introgression of novel alleles of the Myb28 transcription factor
from Brassica villosa, broccoli genotypes have been developed that have
enhanced levels of glucoraphanin. This study seeks to quantify the exposure
of human tissues to glucoraphanin and sulforaphane following consumption
of broccoli with contrasting Myb28 genotypes.
Methods and results: Ten participants are recruited into a three-phase,
double-blinded, randomized crossover trial (NCT02300324), with each phase
comprising consumption of 300 g of a soup made from broccoli of one of
three Myb28 genotypes (Myb28B/B, Myb28B/V, Myb28V/V). Plant myrosinases
are intentionally denatured during soup manufacture. Threefold and ﬁvefold
higher levels of sulforaphane occur in the circulation following consumption
of Myb28V/B and Myb28V/V broccoli soups, respectively. The percentage of
sulforaphane excreted in 24 h relative to the amount of glucoraphanin
consumed varies among volunteers from 2 to 15%, but does not depend on
the broccoli genotype.
Conclusion: This is the ﬁrst study to report the bioavailability of
glucoraphanin and sulforaphane from soups made with novel broccoli
varieties. The presence of one or two Myb28V alleles results in enhanced
delivery of sulforaphane to the systemic circulation.
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Observational studies suggest that di-
ets rich in cruciferous vegetables such
as broccoli are associated with a reduc-
tion in the risk of cardiovascular dis-
ease and cancer.[1] These health bene-
ﬁts have been attributed to degradation
products of glucosinolates—specialized
sulfur-containing glycosides that accu-
mulate within these vegetables.[2–4] These
degradation products are generated ei-
ther due to the action of plant thioglu-
cosidases (‘myrosinases’) that also occur
within these vegetables, but which re-
main spatially separated from glucosino-
lates in the absence of tissue disruption,
or, if these enzymes have been denatured
due to cooking, by microbial thioglucosi-
dases within the human gastrointestinal
tract.[5] Glucosinolates possess an agly-
cone side chain derived from an amino
acid; glucosinolates derived from me-
thionine generate isothiocyanates (ITCs)
upon hydrolysis, while those derived
from tryptophan generate a small num-
ber of indole compounds.[6] Both ITCs
and indoles have been associated with
health- promoting eﬀects.[3] The most abundant glucosinolate
in broccoli is the methionine-derived 4-methylsulﬁnylbutyl glu-
cosinolate (glucoraphanin) that generates the isothiocyanate sul-
foraphane upon hydrolysis. This nonvolatile ITC has been ex-
tensively studied in model systems, and been associated with
many biological processes that may underpin the health bene-
ﬁts attributed to cruciferous vegetables.[4] Foremost among these
is the potent induction of the nuclear factor (erythroid-derived
2)-like 2 (nrf2) transcription factor that regulates the expression
of phase 2 detoxiﬁcation and ‘antioxidant’ genes. Following ab-
sorption, sulforaphane is metabolized through the mercapturic
acid pathway and excreted as predominantly an N-acetyl cysteine
conjugate in urine. Glucoraphanin and sulforaphane may be re-
duced to their methylthiobutyl analogue, commonly known as
glucoerucin and erucin respectively, either through enzymic ac-
tivity by the gutmicrobiota[5] or nonenzymically through changes
in the redox environment.[7]
The level of sulforaphane that human tissue will be exposed
to following consumption of broccoli is dependent upon several
factors. The most important of these are the absolute amount
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of the precursor glucoraphanin in the broccoli itself; the hydrol-
ysis of glucoraphanin by plant myrosinases or the gut micro-
biota; and the extent of absorption from the upper and lower
gastrointestinal tract. Studies with the model plant Arabidopsis
and with Brassica have identiﬁed the Myb28 transcription factor
as having an important regulatory role in the expression of glu-
coraphanin, through modulating the expression of genes associ-
atedwith sulfate assimilation and glucosinolate biosynthesis.[8–10]
Moreover, it has been shown that the Myb28 allele from the
related Brassica species Brassica villosa (Myb28v) when intro-
gressed into a broccoli genetic background to replace the nor-
mal broccoli allele (Myb28B) results in an enhanced expression of
Myb28 mRNA and greater accumulation of methionine-derived
glucosinolates.[8]
In this paper, we seek to explore the consequences of the intro-
gression of one or two Myb28v alleles into broccoli on the phar-
macokinetics of glucoraphanin and sulforaphane following con-
sumption through a three-phase, double blinded, randomized
crossover trial. To simulate likely domestic cooking scenarios, we
denature all endogenous plant myrosinases through blanching
the broccoli prior to developing a broccoli soup through a stan-
dard commercial manufacturing process.
2. Experimental Section
2.1. Materials
BDVacutainer EDTA (purple capped) blood collection tubes were
purchased from Becton Dickinson and Company. DNeasy blood
& tissue kit and RNase (100 mg mL–1) were acquired from Qia-
gen Ltd. TaqMan Drug Metabolism SNP Genotyping Assays and
TaqMan Universal Master Mix II without uracil-N-glycosylase
(UNG) were purchased from Thermo Fischer Scientiﬁc. Sul-
foraphane (CAS 4478-93-7) (purity > 98%) was purchased from
LKT Laboratories. The internal standard N-butylthiocarbamoyl
cysteine (B-ITC) and sulforaphane conjugates including
sulforaphane-glutathione, sulforaphane-cysteine-glycine,
sulforaphane-cysteine, sulforaphane-N-acetylcysteine (-NAC),
and erucin-NAC were synthesized as published in.[11] The
internal standard sinigrin for glucoraphanin was purchased
from Sigma–Aldrich. Blank plasma from healthy participants
with the same diet restriction described in ‘Study design’ was
ordered from Sera Laboratories International Ltd to make stan-
dard curves. DEAE Sephadex A25 and SP Sephadex C25 were
obtained from Amersham Biosciences. Glucoraphanin (CAS
21414-41-5) (purity  95%) and glucoerucin (CAS 21973-56-8)
(purity  97%) were purchased from Cayman Chemical and
from Carl Roth, respectively. All other chemicals were purchased
from Sigma–Aldrich.
2.2. Study Design
Men and woman aged 18–65 years with a BMI between 19.5
and 35 kg m–2 were enrolled into a randomized, double-blinded,
three-phase crossover trial carried out at the Human Nutrition
Unit (HNU) at the Quadram Institute Bioscience (QIB). Par-
ticipants were recruited on the basis of fasted (8 h) screen-
ing blood/urine samples and a completed health question-
naire. With the use of an electronic randomization generator
(www.randomization.com), a randomization sequence was gen-
erated prior to the start of the intervention allocation. Each phase
involved a 48-h preintervention diet restriction, a study day in-
volving a 9 h stay at the HNU and a sample collection the follow-
ingmorning (24 h post soup consumption) followed by awashout
period of 2 weeks. Participants (n = 10) were required to follow
a glucosinolate-free diet as well as avoiding alcohol, spicy food
and garlic for 48 h prior to each study day until the collection
of the 24 h sample for each phase. This dietary restriction was
required to ensure that glucosinolates from other food sources
did not have an impact on the study results. During each study
day, 11 blood samples (10 mL) were collected after the consump-
tion of the soups at the following timepoints: 0, 30, 45, 60, 90,
120, 180, 240, 360, 480 min, and 24 h. Six urine samples were
collected at the following timepoints: 0, 0–2, 2–4, 4–6, 6–8, and
8–24 h. Ethical approval was obtained from the Human Research
Governance Committee at QIB (IFR06/2014) and the NRES East
of England Norfolk Ethics Committee (14/EE/1121). The study
was registered on Clinicaltrials.gov (NCT02300324). Written in-
formed consent of all participants was obtained. The study lasted
from September 2014–August 2015.
2.3. Dietary Intervention
Participants were randomly allocated to one of the three types
of broccoli soups at each phase: (i) 300g Myb28B/B broccoli (stan-
dard broccoli) and stilton soup, (ii) 300gMyb28B/V broccoli (Bene-
forte) and stilton soup, and (iii) 300g Myb28V/V broccoli and stil-
ton soup. Glucoraphanin levels in soups were quantiﬁed using
a validated HPLC–DAD method as described in Saha et al.[12] in-
volving the conversion of glucosinolates to desulfoglucosinolates.
The soups were manufactured by Bakkavor (Lincolnshire, UK)
and frozen immediately. In order to avoid variability in the cook-
ing process, the study team implemented a standard operating
procedure that involved heating the study diet in the microwave
at the HNU for 6 min on the morning of the study phases. All
three types of soups appeared the same and had the same ﬂavor
enabling the blinding for both study scientists and participants.
2.4. Biological Sample Collection and Processing
Blood samples (10 mL) were collected from the intravenous
catheter into EDTA (BD Vacutainer). Aliquots of whole blood
were immediately placed in dry ice for storage at –80 °C for geno-
typing.Whole bloodwas also centrifuged at 1000× g for 15min at
room temperature and plasmawas aliquoted and stored at –80 °C
for analysis of metabolites. Plasma samples were extracted on ice
by adding 20μL of precooled 50% trichloroacetic acid (glucosino-
late analysis) or triﬂuoroacetic acid (sulforaphane analysis), and
10μL of internal standard (B-ITC or sinigrin) to 100μL of plasma
sample. The samples were vortexed for 30 s followed by centrifu-
gation at 17 000 × g at 4 °C for 10 min. The supernatant was
transferred into Thermo Scientiﬁc insert vials and analyzed on
the UPLC–MS/MS and LC–MS/MS for glucoraphanin and sul-
foraphane, respectively.
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Filtered urine aliquots (100 μL) were extracted by the addi-
tion of 890 μL of either ammonium acetate buﬀer and 10 μL
of internal standard (B-ITC) for sulforaphane, or 0.5% formic
acid and 10 μL of internal standard (sinigrin) for glucoraphanin.
Samples were vortexed for 30 s then centrifuged for 10 min at
17 000 × g at 4 °C. The supernatant was transferred into Agilent
vials and analyzed on the UPLC–MS/MS and Agilent 6490 Triple
Quad LC–MS/MS system for glucoraphanin and sulforaphane,
respectively.
2.5. UPLC–MS/MS Analysis of Glucoraphanin in Plasma and
Urine Samples
We developed a novel and highly sensitive method to accurately
detect levels of glucoraphanin and its reduced analogue glu-
coerucin from plasma and urine samples.
Glucoraphanin and glucoerucin analysis was performed on an
Agilent 6490 tandem mass spectrometer equipped with an Agi-
lent 1260 HPLC system (Agilent Technologies, Santa Clara, CA,
USA). The chromatographic separation of glucoraphanin, glu-
coerucin and sinigrin was conducted on a Kinetex 1.7 μm XB-
C18 100 A˚ 100 × 2.1 mm UPLC column. The mobile phase
was composed of MilliQ water containing 0.2% formic acid
(mobile A) and acetonitrile containing 0.2% formic acid
(mobile B). The gradient started at 5% mobile phase B increas-
ing over 7 min to 80% mobile phase B and ﬁnally reequilibrat-
ing to 5% mobile phase B for 2 mi. The total run time was
10 min, and the ﬂow rate was 300 μL min–1. The LC eluent ﬂow
was sprayed into the mass spectrometer interface without split-
ting. The MS/MS system was equipped with an ESI source oper-
ated in negative-ion detection mode. Nitrogen gas was used for
nebulation, desolvation, and collision. The analytes were moni-
tored in multiple-reaction monitoring (MRM) mode. The MRM
precursor, product ions, and collision energy were optimized by
Agilent optimizer software. The transitions of precursor ions to
product ions (m/z) and some optimized MS operating parame-
ters of the analytes are described in Supporting Information Ta-
ble S1. Other settings for the mass spectrometer were as follows:
gas ﬂow 16 L min–1 at 200 °C, nebulizer pressure 50 psi, sheath
gas ﬂow 11 Lmin–1 at 300 °C, and capillary voltage 3500 V. Quan-
tiﬁcation was performed using the ratio of the integrated peak
area of glucoraphanin and glucoerucin to that of sinigrin and was
calculated with MassHunter Workstation software (version B.06,
Agilent Technologies).
Matrixmatch calibration curvewas used to plot the ratios of the
analyte peak area to the sinigrin peak area at nine diﬀerent con-
centrations of authentic standard ranging from0.0 to 2.0μgmL–1
for both glucoraphanin and glucoerucin. The linearity of the re-
sponse was assessed by means of least-squares linear regression.
2.6. LC–MS/MS Analysis of Sulforaphane and its Conjugates in
Plasma and Urine Samples
Sulforaphane and conjugates were analyzed in plasma and urine
samples as described before[13] with slightmodiﬁcations.Metabo-
lites were separated on the HPLC Phenomenex Luna 3u C18 (2)
100A 100 × 2.1 mm column with a ﬂow of 0.25 mL min–1. All
MRM transitions (precursor and products ions) and collision en-
ergy were optimized by Agilent optimizer software. The source
parameters included a gas temperature at 200 ˚C with a gas ﬂow
of 12 L min–1, a sheath gas temperature at 400 ˚C with a sheath
gas ﬂow of 12 Lmin–1, a nebuliser pressure of 60 psi, and capillary
voltage at 4000 V. In addition, erucin-NAC was also measured by
using the same method.
2.7. Genotyping
Genomic DNA was extracted from 100 μL whole blood samples
using the Qiagen DNeasy blood & tissue kit from Qiagen as per
manufacturer’s instructions. The TaqManDrugMetabolismSNP
Genotyping Assay for GSTM1 (assay ID: C4420299720) was used
to determine glutathione S-transferasemu 1 (GSTM1) gene dele-
tion and allelic variance, using the AB StepOnePlus instrument.
Data were quantiﬁed relative to a two-copy gene control, a region
in IVS10 of the breast cancer 1, early onset (BRCA1, NM 007294)
gene.[14]
2.8. Statistical Analysis
The study was powered to detect a signiﬁcant (p<0.05) diﬀerence
in mean total urinary thiol excretion of 18 μmol between con-
sumption of standard broccoli (Myb28B/B) and stilton soup and
Beneforte R© broccoli (Myb28V/B) and stilton soup, with a power
of 80%. Pharmacokinetics parameters of the plasma data (AUC),
Tmax (time of maximum concentration), Cmax (maximum con-
centration) were calculated on Prism (GraphPad Software, La
Jolla California USA, www.graphpad.com). Urine data were an-
alyzed to give total excreted (Total Excrete) and the percentage
excreted based on the knowledge of the soup compositions (Total
Excrete %). Response variables were modeled using sequential
analysis of variance. Standard model diagnostics were applied
for example transformations of the response or removal of po-
tential outliers. Signiﬁcance levels for multiple comparisons are
based on Tukey’s honest signiﬁcant diﬀerence. The statistician
was blinded during the analysis of the data.
3. Results
3.1. Subject Recruitment
Ten participants (seven females and three males) were recruited
into the study (Figure 1) and completed all three phases without
any adverse eﬀects. The participants had the following baseline
characteristics (age 42.9 ± 17.4 years, height 170.9 ± 10.6 cm,
weight 73.6 ±13.6 kg, BMI 25.2 ± 3.2 (kg m–²). Out of ten partic-
ipants, six wereGSTM1-positive (either homozygous or heterozy-
gous for a functional GSTM1 allele), and four wereGSTM1-null.
The 40% occurrence ofGSTM1-null genotype in this small study
sample is within the expected range of 39–62% for Caucasians.[15]
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Figure 1. Flow diagram for participant recruitment.
Figure 2. Concentration of glucosinolates in the soups with diﬀerent broccoli genotypes. Glucosinolates measured includes glucoraphanin (4-MSB,
4-methylsulphinylbutyl), 3-methylsulphinylpropyl (3-MSP), indolylmethyl (IND), 1-hydroxy-indolylmethyl (OHIND), 1-methoxy-indolylmethyl (1-MIND),
and 4-methoxy-indolylmethyl (4-MIND). Data are represented as mean ± SD (n = 10, Myb28B/B, Myb28B/V soups; n = 4, Myb28V/V soups). Statistical
analysis of the data was undertaken by two-way analysis of variance with Dunnett’s multiple comparisons test (**p ˂ 0.01 and ***p˂0.0001 vs Myb28B/B
broccoli soup).
3.2. Glucosinolate Levels in the Intervention Soups
The glucosinolate analyses of the three types of broccoli soups
were consistent with their Myb28 genotype. Among the glu-
cosinolates derived from broccoli, the predominant glucosino-
late was glucoraphanin (Figure 2). Myb28V/V and Myb28B/V broc-
coli soups contained 452 ± 10.6 μmoles glucoraphanin per
300 mL portion and 280 ± 8.8 μmoles glucoraphanin per
300 mL portion respectively, approximately ﬁve- and threefold
greater glucoraphanin levels compared to Myb28B/B broccoli
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Figure 3. Plasma concentrations (μm) of intact glucoraphanin (A) and sulforaphane (B) following consumption of Myb28B/B (84μmoles glucoraphanin
per 300 g soup), Myb28B/V (280 μmoles glucoraphanin per 300 g soup), and Myb28V/V (452 μmoles glucoraphanin per 300 g soup) broccoli soups. The
samples were analyzed by UPLC–MS/MS and LC–MS/MS for glucoraphanin and sulforaphane, respectively. Samples were analyzed for sulforaphane
metabolites including sulforaphane-glutathione, sulforaphane-cysteine, sulforaphane–cysteine-glycine, and sulforaphane-NAC. Data (n = 10) are repre-
sented as mean ± SD.








p-Value for broccoli genotypes












AUC (μmol h L–1) 0.05 ± 0.05 0.15 ± 0.08 0.24 ± 0.11 <0.0001 <0.0001 <0.0001 <0.05
Cmax (μmol L–1) 0.01 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 <0.0001 <0.0001 <0.0001 <0.01
Tmax (h) 2.20 ± 1.16 2.23 ± 0.90 2.25 ± 0.95 0.8006
Concentration at 24 h (μmol L–1) ˂0.1 ˂0.1 ˂0.1 0.8389
Glucoraphanin and glucoerucin in urine
Total excreted in 24 h (μmoles) 0.54 ± 0.29 1.44 ± 0.66 2.12 ± 0.98 <0.0001 <0.0001 <0.0001 <0.05
Percentage excreted 24 h after ingestion % 0.64 ± 0.34 0.51 ± 0.24 0.47 ± 0.22 0.6053
Analysis modeled using sequential analysis of variance. The variables including AUC, total excreted, and percentage excreted underwent a square root transformation, Cmax
and Tmax underwent a log transformation. Concentration at 24 h underwent a transformation of (y + 9.5463e-05)–1. Signiﬁcance level for mutliple comaprisons was analyzed
using Tukey’s honest signiﬁcance test.
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Figure 4. Urinary excretion of intact glucoraphanin and glucoerucin (μmoles) in 24 h following consumption of Myb28B/B (84 μmoles glucoraphanin
per 300 g soup), Myb28B/V (280 μmoles glucoraphanin per 300 g soup), and Myb28V/V (452 μmoles glucoraphanin per 300 g soup) broccoli soups.
Cumulative excretion of glucoraphanin/glucoerucin (A), and the total urinary excretion of glucoraphanin/glucoerucin (B) measured in urine by UPLC–
MS/MS. Data (n= 10) are represented asmean± SD. Total urinary excretion data underwent square root transformation followed by analysis by one-way
analysis of variance with Tukey’s honest signiﬁcance test (***p ˂ 0.0001 vs My28B/B broccoli soup).
soup that contained 84± 2.8 μmoles glucoraphanin per 300 mL.
Glucoerucin, sulforaphane, and erucin were not present in the
soups.
3.3. Pharmacokinetic Proﬁle of Glucoraphanin and its Reduced
Analogue
Plasma and urine samples collected from participants were
analyzed by UPLC–MS/MS to assess the bioavailability of
unmetabolized glucoraphanin and its reduced analogue glu-
coerucin. Glucoraphanin was detected in both plasma and urine
samples, and both glucoraphanin and glucoerucin were found
in urine. Glucoraphanin was detectable in plasma within 30
min, peaked at 2 h and then decreased to undetectable levels by
24 h (Figure 3A, Table 1). The AUC and Cmax for glucoraphanin
from broccoli with either one or two Myb28V alleles was sig-
niﬁcantly greater compared to broccoli without Myb28V alleles
(p < 0.0001, Table 1). Glucoraphanin and glucoerucin were de-
tected in urine within 2 h after consumption from all three types
of broccoli soups. The cumulative amount of glucoraphanin and
glucoerucin increased until 8 h after consumption (Figure 4A). A
greater amount of glucoraphanin was excreted in the urine fol-
lowing consumption of the soups with either one or two Myb28V
alleles (Figure 4B).
3.4. Pharmacokinetics of Sulforaphane and its Conjugates
Within 30 min of consumption of all three types of soups,
sulforaphane, its glutathione conjugate, and derivatives (‘sul-
foraphane metabolites’) were detected in plasma samples
(Table 2, Figure 3B). Tmax occurred between 6 and 9 h following
consumption. AUC and Cmax were signiﬁcantly greater for broc-
coli possessing one or two Myb28V alleles compared to standard
broccoli (Table 3). Approximately 35% of sulforaphane occurred
unconjugated in the plasma (Table 2). Within 1 h of consump-
tion, sulforaphane and metabolites were detected in the urine
(Figure 5). The cumulative amount of sulforaphane and metabo-
lites excreted in the urine was signiﬁcantly higher following con-
sumption of the soups with Myb28V/V and Myb28B/V than with
Myb28B/B (Figure 5A, Table 3).
To explore whether the GSTM1 genotype inﬂuenced the
metabolism of sulforaphane and metabolites, pharmacokinetic
parameters were stratiﬁed according toGSTM1 genotypes. There
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Table 2. Summary table of the percentage of individual sulforaphane








Mean ± SD (%) Mean ± SD (%) Mean ± SD (%)
Metabolites in plasma over 24 h
Sulforaphane 32.20 ± 17.29 34.59 ± 14.67 36.58 ± 14.35
Sulforaphane-
glutathione
34.57 ± 21.74 33.01 ± 23.80 30.45 ± 21.21
Sulforaphane-cysteine 8.93 ± 9.93 5.54 ± 3.53 8.77 ± 8.80
Sulforaphane–cysteine-
glycine
21.60 ± 11.81 22.22 ± 10.27 20.23 ± 7.38
Sulforaphane-NAC 2.70 ± 1.79 4.63 ± 4.29 3.97 ± 2.84
Metabolites in 24-h urine excretion
Sulforaphane 8.53 ± 5.57 5.66 ± 3.04 5.41 ± 2.20
Sulforaphane-NAC 57.78 ± 11.73 49.46 ± 14.08 51.26 ± 11.07
Sulforaphane-cysteine 18.29 ± 6.18 19.15 ± 9.20 21.08 ± 5.61
Erucin-NAC 20.93 ± 9.04 25.30 ± 16.73 21.15 ± 13.51
Sulforaphane-cysteine-
glycine
0.48 ± 0.90 0.44 ± 0.72 1.11 ± 2.74
Data (n = 10) is represented as mean ± SD. The percentage was calculated as the
concentration of each individual metabolite (μm) of the total concentration of sul-
foraphane and metabolites (μm).
was no signiﬁcance on the plasma pharmacokinetics (AUC, Cmax,
and Tmax) and the urinary excretion between GSTM1-null and
GSTM1-positive participants (p > 0.05, data not shown).
3.5. Inter-Individual Variation in the Percentage Urinary Excretion
of Glucoraphanin and Sulforaphane
The percentage urinary excretion, represented as the amount of
sulforaphane and metabolites excreted in the urine relative to
the glucoraphanin consumed, exhibited considerable variation
between individuals but was relatively constant for any one in-
dividual regardless of which broccoli genotype was consumed,
varying from15% for participant J to less than 3% from partic-
ipant A. Likewise, there was variation among individuals in their
excretion of glucoraphanin as a percentage of intake (Figure 6).
There was not a signiﬁcant correlation between the % excreted as
sulforaphane and as glucoraphanin, suggesting that these were
determined by diﬀerent metabolic processes (Supporting Infor-
mation Figure S1).
4. Discussion
Observational studies suggest that people who consume more
than four or ﬁve portions of cruciferous vegetables per week have
reduced risk of cancer at a number of sites and other chronic
disease.[1,16–20] A multitude of studies in cell and animal models
have implicated the ITC sulforaphane in these health-promoting
eﬀects,[4] despite very little evidence in humans. To facilitate
human studies that could attempt to dissect the eﬀect of sul-
foraphane from other nutritional factors within broccoli, novel
broccoli Myb28 genotypes have been developed with enhanced
levels of the sulforaphane precursor, glucoraphanin. The aim of
this study was to quantify the pharmacokinetics of sulforaphane
derived from these novel broccoli genotypes in the absence of
any plant-derived myrosinase activity, and, in so doing, evaluate
whether the enhanced glucoraphanin content in the plant tissue
and processed food results in enhanced levels of sulforaphane in
plasma. In addition, we sought to investigate whether any of the
unmetabolized glucoraphanin is absorbed, facilitated through
the development of a new UPLC–MS/MS method as described
above.
For both Cmax and AUC, the level of sulforaphane and its
metabolites in plasma was approximately ﬁvefold higher fol-
lowing consumption of soup from the homozygous Myb28V/V







p-Value for broccoli soup











Sulforaphane and metabolites in plasma
AUC (μmol h L–1) 1.99 ± 1.31 4.92 ± 3.77 8.08± 6.60 <0.0001 ˂0.01 <0.0001 0.0905
Cmax (μmol L–1) 0.17 ± 0.12 0.37 ± 0.26 0.61 ± 0.40 0.0001 ˂0.01 0.0001 0.0683
Tmax (h) 6.10 ± 2.23 7.40 ± 0.97 9.20 ± 5.27 ˂0.05 0.5258 ˂0.05 0.2301
Concentration at 24 h (μmol L–1) 0.02 ± 0.01 0.07 ± 0.06 0.09 ± 0.05 <0.0001 ˂0.01 <0.0001 0.1797
Sulforaphane and metabolites in urine
Total excreted in 24 h (μmoles) 8.74 ± 4.95 23.14 ± 16.17 39.98 ± 26.22 <0.001 ˂0.05 <0.001 ˂0.01
Percentage excreted 24 h after ingestion % 10.40 ± 5.90 8.26 ± 5.78 8.85 ± 5.80 0.5727
Analysis modeled using sequential analysis of variance. The variables underwent log transformation except for plasma concentration at 24 h, which underwent a square
root transformation. Signiﬁcance level for multiple comparisons was analyzed using Tukey’s honest signiﬁcance test. ‘sulforaphane metabolites’ refers to sulforaphane,
sulforaphane-glutathione, sulforaphane-cysteine, sulforaphane–cysteine-glycine, and sulforaphane-NAC in plasma and sulforaphane, sulforaphane-NAC, sulforaphane-
cysteine, erucin-NAC, and sulforaphane–cysteine-glycine in urine.
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Figure 5. Urinary excretion of sulforaphane and metabolites (μmoles) in 24 h following consumption of Myb28B/B (84 μmoles glucoraphanin per 300 g
soup), Myb28B/V (280 μmoles glucoraphanin per 300 g soup), and Myb28V/V (452 μmoles glucoraphanin per 300 g soup) broccoli soups. Cumulative
excretion (A) and total urinary excretion (B) of sulforaphane and metabolites in urine samples analyzed by LC–MS/MS. Samples were analyzed for
sulforaphane metabolites including erucin-NAC, sulforaphane-cysteine, sulforaphane–cysteine-glycine, and sulforaphane-NAC. Data (n = 10) are repre-
sented as mean ± SD. Total urinary excretion data underwent log root transformation followed by analysis by one-way analysis of variance with Tukey’s
honest signiﬁcance test (*p < 0.05 and ***p ˂ 0.001 vs My28B/B broccoli soup).
broccoli genotype, and threefold higher for the heterozygous
Myb28V/B broccoli genotype, compared to the standardMyb28B/B
broccoli (Figure 3B, Table 1). These values reﬂect the diﬀer-
ences in the glucoraphanin content of the broccoli. Intact gluco-
raphanin was also detected in the plasma and urine and, as with
sulforaphane, the relative amounts in plasma and urine reﬂected
the levels that were present in the broccoli (Figure 3A and 3B).
The Tmax for glucoraphanin of 2 h is indicative of absorption
from the upper GI tract, in contrast to themuch later Tmax for sul-
foraphane indicative of absorption from the lower GI tract follow-
ing microbial metabolism of glucoraphanin (Figure 3A and 3B).
The excretion of sulforaphane as a percentage of glucoraphanin
consumed varied between 2 and 15%. The consistent nature of
this value for each volunteer regardless of which broccoli geno-
type they consumed is notable (Figure 6). The variation among
volunteers is likely due to diﬀerences in their gut microbiota and
their ability to metabolize glucoraphanin.
The results from the current study are consistent with that re-
ported by Gasper at al.[21] In this previous study, glucoraphanin
was converted to sulforaphane prior to consumption, unlike the
current study, and it was shown that consuming a threefold
greater amount of sulforaphane led to a threefold greater level
in plasma. In this case, as may be expected, Tmax occurred af-
ter about 2 h due to the lack of a need for microbial metabolism
of glucoraphanin, and a larger percentage of the consumed sul-
foraphane (40–90%) was accounted for in the urine after 24 h.
This previous study also indicated that GSTM1 genotype was a
factor in determining the extent of sulforaphane excretion. This
was not observed in the current study. This may be because the
inter-individual variation in glucoraphanin conversion by the gut
microbiota to sulforaphane obscures any potential eﬀect of geno-
type, and a much larger study would be required to detect any
eﬀect of GSTM1. The expected Cmax of sulforaphane in the cur-
rent study from the standard broccoli was higher than that which
might have been expected based upon studies of Saha et al.[12]
and Vermeulen et al.[22] This may be due to the use of a dif-
ferent food matrix as the soups used in the current study were
rich in fat and other nutrients that may facilitate greater release
of glucoraphanin from plant tissue within the gastrointestinal
tract
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Figure 6. Percentage of glucoraphanin (A) and sulforaphane (B) excreted in the urine following consumption of the ingested dose of glucoraphanin in
the broccoli soups, Myb28B/B (84 μmoles glucoraphanin per 300 g soup), Myb28B/V (280 μmoles glucoraphanin per 300 g soup), and Myb28V/V (452
μmoles glucoraphanin per 300 g soup). Urine samples collected from participants (A–J) were analyzed for glucoraphanin, glucoerucin, sulforaphane,
and its metabolites including sulforaphane, erucin-NAC, sulforaphane-cysteine, sulforaphane–cysteine-glycine, and sulforaphane-NAC.
Previous studies have also reported the presence of unconju-
gated sulforaphane and its thiol conjugates in plasma and urine,
as reported in the present study, although there are diﬀerences
in its relative abundance compared to its thiol conjugates.[12,23]
Consistent with other ﬁndings, the most abundant metabo-
lite excreted in urine was sulforaphane-NAC.[12,21,23] Erucin-NAC
was the second major metabolite excreted with consumption of
all three types of soups. Glucoerucin was not detected in the
broccoli soups. The erucin-NAC may be either derived from
conversion of glucoraphanin to glucoerucin in the gastroin-
testinal tract and the subsequent generation of erucin ITC
by the gut microbiota, or the reduction of sulforaphane post
absorption.[5,7,12]
It is assumed that the glucoraphanin that was not accounted
for by the urinary excretion of sulforaphane metabolites or glu-
coraphanin (and their reduced analogues) would have been ex-
creted with faeces but further study is necessary.
In conclusion, this study has provided evidence that enhanc-
ing glucoraphanin content in broccoli through the simple intro-
gression of B. villosa alleles of a single Myb28 gene results in en-
hanced exposure of human tissues to sulforaphane in a manner
that may be expected to provide health beneﬁts. This is main-
tained when glucoraphanin is delivered in a complex processed
food, i.e. soups, and will allow for the future design of long-term
double-blinded clinical studies to evaluate health beneﬁts, with
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